相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer
Ilaria Alborelli et al.
JOURNAL OF PATHOLOGY (2020)
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
Antoine Italiano et al.
LANCET ONCOLOGY (2020)
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study
Kai-Keen Shiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al.
NATURE MEDICINE (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Tumour-Associated Macrophages (TAMs) in Colon Cancer and How to Reeducate Them
M. A. F. Yahaya et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2019)
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi et al.
MOLECULAR CANCER (2019)
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Pengfei Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Tanios S. Bekaii-Saab et al.
LANCET ONCOLOGY (2019)
Novel approaches for molecular targeted therapy against hepatocellular carcinoma
Yuji Eso et al.
HEPATOLOGY RESEARCH (2018)
NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models
Bryan D. Smith et al.
CANCER RESEARCH (2016)
Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches
Pnina Brodt
CLINICAL CANCER RESEARCH (2016)
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
Tai Hato et al.
IMMUNOTHERAPY (2016)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
Zoran Gatalica et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
Lotfi Abou-Elkacem et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy
Anna Johansson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial
Sarah Zohar et al.
CONTEMPORARY CLINICAL TRIALS (2008)
分享论文
